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Summary 
5-Azacytidine was originally developed to treat human myelogenous leukemia. However, interest in 
this compound has expanded because of reports of its ability to affect cell differentiation and to alter 
eukaryotic gene expression. In an ongoing attempt to understand the biochemical effects of this 
compound, we examined the effects of 5-azacytidine on mitosis and on micronucleus formation in 
mammalian cells. In L5178Y mouse cells, 5-azacytidine induced micronuclei at concentrations at which 
we and others have already reported its mutagenicity at the tk locus. Using CREST staining and 
C-banding studies, we showed that the induced micronuclei contained mostly chromosomal fragments 
although some may have contained whole chromosomes. By incorporating BrdU into the DNA of SHE 
cells, we determined that micronuclei were induced only when the compound was added while the cells 
were in S phase. Microscopically visible effects due to 5-azacytidine treatment were not observed until 
anaphase of the mitosis following treatment or thereafter. 5-Azacytidine did not induce micronuclei via 
interference with formation of the metaphase chromosome arrangement in mitosis, a common mecha-
nism leading to aneuploidy. SupravitalUV microscopy revealed that chromatid bridges were observed in 
anaphase and, in some cases, were sustained into interphase. In the first mitosis after 5-azacytidine 
treatment we observed that many cells were unable to perform anaphase separation. All of these 
observations indicate that 5-azacytidine is predominantly a clastogen through its incorporation into 
DNA. 
Correspondence: Dr. William J. Caspary, NIEHS, P.O. Box 
12233, Research Triangle Park, NC 27709, USA. 
Abbreviations: BrdU, bromodeo:xyuridine; BSA, bovine serum 
albumin; DES, diethylstilbestrol; DMSO, dimethyl sulfoxide; 
FITC, fluorescein isothiocyanate; PBS, phosphate-buffered 
saline; SHE cells, Syrian hamster embryo cells; TFf, trifluo-
rothymidine. 
5-Azacytidine was originally developed to treat 
human myelogenous leukemia (Von Hoff et al., 
1976). However, interest in this compound has 
expanded because of reports of its ability to af-
fect cell differentiation and to alter eukaryotic 
gene expression (Holliday, 1989) 
Most of 5-azacytidine's biological activity, in-
cluding its ability to induce gene expression, has 
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been attributed to its capability to induce DNA 
hypomethylation. Jones and coworkers demon-
strated a correlation between the ability of a 
series of cytidine analogs, including 5-azacytidine, 
to induce differentiation and their ability to pre-
vent DNA methylation (Constantinides et al., 
1977; Jones and Taylor, 1980; Taylor and Jones, 
1979). However, 5-azacytidine has also been 
shown to be mutagenic in a variety of cell systems 
(Amacher and Turner, 1987; Call et al., 1986; 
McGregor et al., 1989; Schmuck et al., 1988) and 
using molecular biological techniques, we have 
found that the compound induces point muta-
tions in AS52 cells (Daston et al., 1992; Kelecsenyi 
et al., 1993). We (McGregor et al., 1989) have 
also evaluated the same cytidine analogs evalu-
ated by Jones and coworkers (Constantinides et 
al., 1977; Jones and Taylor, 1980; Taylor and 
Jones, 1979) for their ability to induce trifluo-
rothymidine resistance (TFfr) in L5178Y mause 
cells. We found that their mutagenic potency 
correlated with their reported ability to induce 
differentiation in C3H10T1/2 cells (Jones and 
Taylor, 1980). Thus, it has been reported that 
both the mutagenic and hypomethylating ability 
of these azacytidine analogs correlated with their 
ability to induce differentiation of cells in culture. 
5-Azacytidine has also been shown to affect 
chromosome structure. We have reported that 
this compound induces micronuclei in SHE cells 
(Stopper et al., 1992). Effects such as chromo-
some decondensation, endoreduplication and 
segmentation have also been reported (Hori, 1983; 
Parrow et al., 1989; Schmid et al., 1984). Major 
perturbations of cell cycle kinetics tagether with 
elevated rates of endomitosis and tetraploidy were 
found in human fibroblast-Iike cells from skin 
and amniotic fluid (Poot et al., 1990). This is 
consistent with the findings of Zatsepina et al. 
(1989) who showed that 5-azacytidine blocked pig 
kidney cells in G2 phase of the cell cycle. 
5-Azacytidine is clastogenic. Shelby and 
coworkers have evidence that 5-azacytidine treat-
ment of CHO cells produced a dose dependent 
increase in chromosome aberrations in these cells 
in culture (Shelby, 1992). The compound was also 
found to be clastogenic in plant cells (Fucik et al., 
1970) and human lymphoblasts from a male donor 
(Lavia et al., 1985). Call et al. (1986) failed to 
show an increase in chromosomal aberrations in 
human lymphoblasts in culture and V an Humme-
len and coworkers asserted that the compound is 
an aneugen (V an Hummelen et al., 1992) in mouse 
bone-marrow cells in vivo. 
5-Azacytidine induces micronuclei (Stopper et 
al., 1992). Micronuclei can contain chromosomal 
fragments or whole chromosomes. The contents 
of micronuclei depend on the mechanisms lead-
ing to their formation. The critical Iesion in the 
formation of chromosomal aberrations is pre-
sumed to be double-strand breaks while aneu-
ploidy is thought to be induced by disturbances in 
chromosome distribution during mitosis. 
The purpose of the present work is to charac-
terize the contents of 5-azacytidine-induced mi-
cronuclei and to examine the mitotic disturbances 
that may be involved in micronucleus induction 
by 5-azacytidine treatment. In addition to SHE 
cells which we have previously used (Stopper et 
al., 1992), we chose L5178Y mause cells because 
of their low incidence of spontaneaus micronuclei 
(Kirchner et al., 1992) and because we have previ-
ously shown that 5-azacytidine induces TFf resis-
tance in these cells (McGregor et al., 1989). In 
this paper we report that approximately 80% of 
the 5-azacytidine induced micronuclei did not 
stain for kinetochores and for centromeric hete-
rochromatic DNA suggesting that 5-azacytidine is 
primarily a clastogen. However, a small percent-
age of the micronuclei could contain whole chro-
mosomes. We, then, examined 5-azacytidine-
treated cells for the mitotic disturbances that 
could Iead to an aneugenic response. 
Materials and methods 
Chemicals. 5-Azacytidine (MW = 244), bere-
nil (MW = 515.5), ethionine (MW = 163.2), DES 
(MW = 268.4), bisbenzimid 33258 and 33342, 
BrdU and anti-mause IgG FITC-conjugated anti-
body, anti-a-tubulin antibody and FITC-con-
jugated goat anti-human antibody were pur-
chased from Sigma Chemical Co., St. Louis, MO, 
USA. DMSO was acquired from Aldrich Co., 
Nettetal, Germany and CREST-serum (anti-
kinetochore antibody) was purchased from Anti-
hodies Inc, Davis, CA, USA. Anti-BrdU fluores-
cein (monoclonal antibody against BrdU) was ac-
quired from Boehringer, Mannheim, Germany. 
Cell culture. L5178Y tk+l- mouse Iymphoma 
cells, clone 3.7.2c (Clive et al., 1972) were rou-
tinely cultured in suspension in RPMI-1640 sup-
plemented with 95 unitsjml penicillin, 95 1-'g/ml 
Streptomycin, 0.25 mgjml L-8lutamine, 107 1-'8/ml 
sodium pyruvate and 10% heat-inactivated horse 
serum (Boehringer Mannheim, Germany ). Cell 
cultures were grown in humidified atmosphere 
with 5% co2 in air at 37°C. Allexperiments with 
SHE cells were performed with tertiary or qua-
ternary cultures derived from 13-day old Syrian 
hamster embryos. The culture medium used was 
IBR-modified Dulbecco's reinforced medium 
(Grand Island Biological Co.) supplemented with 
100 U /ml penicillin and 100 1-'8/ml strepto-
mycin, 3.7 8/1 NaHC03 and 15% fetal calf serum 
(Gibco, Karlsruhe, Germany). Cell cultures were 
grown in humidified atmosphere with 12% co2 
in air at 37°C. 
Micronucleus assay. Exponentially growing 
L5178Y mouse cells were treated with chemieals 
for 4 h. If chemieals were dissolved in DMSO 
' the final concentration of DMSO did not exceed 
1%. Mt er removing the chemieals by medium 
replacement, the cells were incubated for 5-20 h 
as specified in the table legends. At the indicated 
times the cells were deposited onto glass slides by 
cytospin centrifugation. Fixation was performed 
with methanol (- 20°C, 1 h). For staining, the 
slides were washed with distilled water, incubated 
with bisbenzimid 33258 (1 p.gjml, 5 min), washed 
3 times with distilled water and mounted for 
fluorescence microscopy. U sing a magnification 
or 1250 X, we scored the number of nuclei and 
micronuclei (3 slides with 2000 nuclei scored per 
slide). 
Kinetochore staining. Kinetachore staining 
was achieved by incubatin8 the fixed cell prepara-
tions (after rinsing with PBS) with CREST serum 
(60 min) in a humidified chamber at 37°C. After 
rinsing with PBS, the cells were incubated as 
before with FITC conju8ated goat anti-human 
antibody (diluted 1 : 100 in PBS), rinsed again and 
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counter stained with bisbenzimid 33258 (11-'g/ml, 
5 min). 
C-Banding. L5178Y cells were fixed and 
stained according to the conventional technique 
used for karyotyping (Sumner, 1972). Micronuclei 
were scored for the presence of dark stained 
c-band regions using a magnification of 1250 x . 
· (The only micronuclei counted were those in cells 
where dark staining heterochromatic re8ions in 
the nucleus were clearly visible.) 
Analysis of metaphase ring a"angement. We 
treated L5178Y cells for 4 h with the chemical. 
The cells were fixed at times indicated in table 3. 
Fixation and staining was performed as described 
for micronuclei above. Due to cytospin prepara-
tion, chromosomes arranged at metaphase plate 
are seen as a ring arran8ement. Metaphases 
showing a ring arrangement were evaluated for 
Chromosomes dislocated from the ring. Spindie 
staining was achieved by applying anti-a-tubulin 
antibody (diluted 1 : 250 in PBS) and FITC-
labelled anti-mause antibody (diluted 1 : 100 in 
PBS) according to the procedure given for kineto-
chore staining. 
SupravitalUV microscopy. SupravitalUV mi-
croscopy was performed according to the method 
of Schiffmann and DeBoni (1991) using SHE 
cells. This method allows the observation of the 
spacial arrangement of chromatin elements 
throughout mitosis in living cells. The cells were 
incubated with culture medium containing 5-
azacytidine and bisbenzimid 33342 (0.1 JJ.g/ml; 
staining of cellular DNA) for 4 h. Then the 
medium was replaced by culture medium contain-
ing bisbenzimid but no 5-azacytidine. Observation 
of the cells using supravital UV microscopy was 
carried out immediately after addition of 5-
azacytidine and up to 30 h thereafter. Control 
cells were untreated except bisbenzimid staining. 
Due to the fact that cells are followed individu-
ally for a number of hours, experiments were 
limited to low cell numbers. 
BrdU incorporation. SHE cells were plated in 
35-mm Petri dishes containing glass ·coverslips 
and allowed to grow. Then, the cell culture 
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Fig. l. Dose-response of 5~azacytidine induced micronuclei. L5178Y cells were treated with the indicated concentrations for 4 h 
and fixed 18 h later. Cells treated with 37 p.M DES showed 28.0 ± 6.8 micronuclei per 2000 cells. 
medium was replaced by culture medium contain-
ing the chemical tobe tested and BrdU (10 ~M). 
Following an incubation period of 2.5 h the corn-
pound and BrdU were removed by changing the 
medium and washing the cells with culture 
medium once. After 12 h, the cells were ftxed 
with methanol for at least 60 min at - 20°C. 
Coverslips were washed with PBS twice and 
treated with HCI (1.5 M). Mter 30 rnin they were 
washed twice within a 10-min period with 
TABLE 1 
Na 2 B40 7 (0.1 M, pH 8.5) for neutralization after 
the acid treatment. They were then washed twice 
with PBS within a 10-min period. 20 ~tl of anti-
BrdU fluorescein antibody (50 ~gjml in PBS 
with 0.1% BSA) were dropperl onto another slide 
and covered with the inverted coverslip. After 
incubation (30-45 min, 37°C) in a hurnidified 
chamber, they were washed with PBS, counter-
stained with bisbenzimid (1 ~g/ml, 5 min) and 
mounted for fluorescence microscopy. Nuclei and 
KINETOCHORE STAINING OF MICRONUCLEI IN L5178Y CELLS 
Treatment Nurober K + MN per Nurober of induced % induced MN 
100 MN examined K+MN that are K+ 
Vehicle control 22 
5~Azacytidine (1 p.M) 19.0±2.7 16.0 18.6 
DES (37 p.M) 77.3±4.2 72.3 93.5 
Ethionine (80 p. M) 28.0±3.6 24.7 29.0 
Berenil (155 p.M) 27.7±3.2 26.6 28.0 
Cells were treated for 4 h and were flxed and stained after a recovery time of 20, 20, 5, 20 and 6 h for vehicle control, 5-azacytidine, 
DES, ethionine and berenil respectively. 3 slides were prepared from each treated culture and 100 micronuclei from each slide 
evaluated for the presence of kinetochores. Column 2 shows the percentage of micronuclei obseiVed that stain positive for CREST 
antibody. From the dose-response curves we know that the percentage of induced (spontaneous) micronuclei in each population is 
86.2 (13.8), 77.3 (22.7), 85.1 (14.9) and 95.0 (5) respectively. From this and the number of K+ micronuclei in the vebicle control, we 
calculate the number of K + micronuclei that are induced by each chemical (column 3). The fmal column lists the percentage of 
chemically induced micronuclei that stain positive for the presence of kinetochore. K+ means staining positive for the presence of 
kinetochores; MN, micronuclei. 
micronuclei were evaluated at 1250 X magnifica-
tion for the presence of BrdU antibody staining. 
Results 
Induction of micronuclei by 5-azacytidine. 5-
Azacytidine induced an increase in micronuclei at 
doses from 0.1 up to 5 11-M, the highest dose we 
examined (Fig. 1). The micronucleus fraction in-
creased to a value of 26.4 micronuclei per 2000 
cells at 1 11-M. At high er doses no further in-
crease in the micronucleus fraction was observed. 
The spontaneous micronucleus fraction was 3.6 
per 2000 cells. This dose-response curve is com-
parable to the micronucleus results obtained with 
SHE cells {Stopper et al., 1992). 
To determine whether 5-azacytidine is a clas-
togen or an aneugen, we assayed the contents of 
the 5-azacytidine-induced micronuclei for the 
presence of kinetochores by immunofluorescent 
staining using CREST antiborlies (Degrassi and 
Tanzarella, 1988). Our data (Table 1) show that 
18.6% of the 5-azacytidine-induced micronuclei 
stained positive in this assay indicating the ab-
sence of kinetochores in 81.4% of this micronu-
cleus population. Therefore, the majority of 5-
azacytidine-induced micronuclei most likely did 
not contain whole chromosomes, but rather acen-
tric chromosomal fragments. For comparison, 
93.5% of the micronuclei induced by DES, an 
agent known to induce aneuploidy in SHE cells 
TABLE2 
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(Schiffmann and DeBoni, 1991), stained positive 
for kinetochores. 
One criticism of the interpretation of CREST 
staining data is that whole chromosomes with 
damaged kinetochore protein may not stain posi-
tive in this assay. It is also possible that kineto-
chore binding to the chromosome may be dis-
turbed and that such chromosomes may remain 
at the metaphase plate during mitosis. This would 
result in micronuclei with whole chromosomes 
that would not be detected by this technique. 
To investigate this possibility, we performed 
two more experiments. We first stained the mi-
cronuclei with the c-banding technique commonly 
used for the staining of heterochromatic cen-
tromeric DNA regions in metaphase chromo-
somes. Our results (Table 2) show that a signal 
was present in 20% of the vehicle control mi-
cronuclei. Of the 5-azacytidine-induced micronu-
clei, 23.6% stained positive for the presence of 
centromeric heterochromatin. In contrast, 89.7% 
of the DES-induced micronuclei were positive in 
the staining procedure. We then evaluated the 
centromeric heterochromatin regions with bis-
benzimid 33258 which preferentially stains these 
regions in mouse chromosomes. In this experi-
ment, 20% of the micronuclei treated with vehi-
cle control showed a signal (50 micronuclei evalu-
ated). After correcting for the vehicle control, 
27% of the 5-azacytidine-induced cells (100 mi-
cronuclei evaluated) showed a signal. A small 
CENTROMERB STAINING OF MICRONUCLEI IN L5178Y CELLS 
Treatment Number c+ MN per Number of induced % induced MN 
100 MN examined c+ MN that are c+ 
Vehicle control 20 
5-Azacytidine (1 ~-tM) 23.3±2.1 20.5 23.6 
DES (37 p.M) 74.3±7.6 69.3 89.7 
Cells were treated for 4 h and ftxed and stained after a recovery time of 20, 20, 5, vehicle control, 5-azacytidine and DES 
respectively. 3 slides were prepared from each treated culture and 100 micronuclei evaluated for the presence of centromeric DNA. 
Column 2 shows the fraction of micronuclei observed that stain positive for centromeres. From the dose-response curves we know 
that the percentage of induced (spontaneous) micronuclei in each population is 86.2 (13.8) and 77.3 (22.7) respectively. From this 
and the number of c+ micronuclei in the vehicle control (20), we calculate the number of c+ micronuclei that are induced by the 
chemical (column 3). The final column lists the percentage of chemically induced micronuclei that stain positive for the presence of 
centromeres. "C+" means staining positive for the presence of centromeres; MN, micronuclei. 
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Fig. 2. Dose-response of ethionine induced micronuclei. l5178Y mouse cells were treated with the indicated concentrations of 
ethionine for 4 h and fixed 5 h later. The micronuclei fraction for the vehicle control was 3.3±0.5 micronuclei per 2000 cells. 
percentage of centromeres in micronuclei of 5-
azacytidine-treated cells may be without stainable 
kinetochore protein. However, the majority of 
micronuclei contain chromosomal fragments. 
Thus, we conclude that 5-azacytidine is predomi-
nantly a clastogen. 
Treating cells with 5-azacytidine is known to 
resalt in hypomethylated DNA and many of the 
effects of this compound have been attributed to 
this property. Ethionine also prevents DNA 
methylation by inhibiting the enzymatically cat-
alyzed formation of S-adenosylmethionine. This 
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compound induced micronuclei in a dose depen-
dent manner (Fig. 2). 5-Azacytidine has been 
reported to interfere with chromosome condensa-
tion (Fucik et al., 1970; Hori, 1983; Parrow et al., 
1989; Schmid et al., 1984). Berenil, which causes 
chromosome undercondensation by binding to the 
minor groove of the DNA molecule, also induced 
micronuclei (Fig. 3). Of the micronuclei in both 
the ethionine and berenil treated cultures, 28% 
stained positive in the CREST antibody assay for 
kinetochores (Table 1) suggesting fragments of 
chromosomes were present in most of these mi-
0~----~------~----~-----T------~----~----~----~ 
0 10 20 30 40 50 60 70 80 
Concentration (J~g/m1) 
Fig. 3. Dose-response of berenil induced micronuclei. L5178Y mouse cells were treated with the indicated concentrations of 
berenil for 4 h and flxed 5 h later. The micronuclei fraction for the vehicle control was 3.3±0.6 micronuclei per 2000 cells. 
cronuclei. The shapes of the dose-response 
curves and the percentages of kinetochores pres-
ent for both these compounds are similar tothat 
of 5-azacytidine. 
To determine the stage of the cell cycle in 
which 5-azacytidine bad to be added to induce 
micronuclei, we attempted to synchronize L5178Y 
and SHE cells. We tried fetal calf serum with-
drawal, mitotic shake-off (SHE cells only), col-
cemid, aphidicolin and hydroxyurea. Some of the 
methods commonly used for cell synchronization 
induced micronuclei themselves and were not 
suitable for our purposes; others did not achieve 
synchronization of the cell types used. Therefore, 
we used a novel approach to study the effects of 
5-azacytidine in specific cell cycle stages. We 
treated SHE cells for 2.5 h with BrdU and 5-
azacytidine (or DES as a control) concurrently. 
After removing the chemicals, we fixed the cells 
12 h later, a timethat was short enough that cells 
would not pass through a second mitosis since the 
doubling time of SHE cells is 17 h. We evaluated 
each cell and its associated micronucleus, if pres-
ent, for the appearance of BrdU in the chromatin 
material using BrdU antibody staining. The pres-
ence of BrdU indicated that replication or repair 
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had taken place during the time of the pulse 
treatment with 5-azacytidine (DES) and BrdU. 
We counted the number of cells with micronuclei 
in each of the following observed categories: (1) 
cells with BrdU signal in the nucleus and mi-
cronucleus; (2) cells with BrdU signal in the nu-
cleus, but not in the micronucleus; and (3) mi-
cronucleus containing cells with no BrdU (Fig. 4). 
We counted cells treated with the vehicle con-
trol in each of the categories (Fig. 4). Those that 
showed no BrdU in either the nuclei or micronu-
clei must have been in G2 phase during treat-
ment and formed micronuclei during the mitoses 
immediately following treatment or in M phase, 
in which case the rnicronuclei would have been 
formed in the same mitosis in which treatment 
occurred. Cells exposed to the vehicle control in 
G 1 that already bad micronuclei would also ap-
pear in this category. However, those cells ex-
posed in G 1 without micronuclei would not be 
able to form them because they would not have 
bad time to undergo mitosis during the 12 h 
before fixation. Those vehicle control treated cells 
that incorporated BrdU into both the nucleus 
and micronucleus were in S phase during treat-
ment (either with a previously existing micronu-
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Fig. 4. Cell-cycle dependence of micronucleus induction. SHE cells were treated for 2.5 h with 1 p.M 5-azacytidine or 47 p.M DES, 
each with 10 ,...M BrdU. This graph shows the number of cells with micronuclei normalized to 2000 cells evaluated. The first 
category represents those cells that contain BrdU in both the nuclei and their associated micronuclei. The second category consists 
of those cells that possess BrdU in the nuclei but not in their associated micronuclei. In the last category are those cells that have 
not incorporated BrdU in either the nucJei or associated micronuclei. The number of cells evaluated were 10000 for the vehicle 
control, 8000 for 5-azacytidine-treated and 5000 for DES treated. 
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TABLE 3 
METAPHASE RING ARRANGEMENT IN L5178Y CELLS 
Treatment 
1 J.LM 
5-Azacytidine 
5J.LM 
5-Azacytidine 
37J.LM DES 
Vehicle control 
Time 
scored 
(h) 
0 
1 
2.5 
5 
0 
1 
2.5 
5 
0 
0 
Number Number rings with 
mitotic displaced 
rings chromosomes 
300 1 
300 0 
300 0 
335 0 
300 0 
300 0 
300 0 
300 0 
264 12 
300 0 
Cells were treated with 5-azacytidine or DES for 4 h and fixed 
at the indicated times after that. Metaphase ring arrange-
ments were analyzed for displaced chromosomes. 
cleus or forming one in the next mitosis) or in a 
non-replicative phase of the cell cycle and under-
going repair. 
5-Azacytidine treatment resulted in an in-
creased number of cells with BrdU incorporation 
into the DNA of the nucleus and micronucleu~ 
compared to the control. DES-induced no in· 
crease in this category. Both compounds in-
creased the number of cells containing BrdU in 
the nucleus but not in the micronucleus. The 
number of cells showing no BrdU in the nucleus 
or in the micronucleus increased after DES but 
not after 5-azacytidine treatment. In fact, 5-
azacytidine decreased the number of cells in this 
category. 
Effects of 5-azacytidine on the mitotic appara-
tus. Because of reports that 5-azacytidine is an 
aneugen (Van Humrnelen et al., 1992) and our 
data showing that some of the micronuclei could 
contain whole chromosomes, we decided to exam-
ine whether mechanisms known to induce aneu-
ploidy are operable in the response of L5178Y 
cells to this compound. Many aneuploidy induc-
ing agents affect the metaphase chromosome ring 
arrangement and spindie morphology. Conse-
quently, we compared the effects of 5-azacytidine 
with DES, an aneuploidy inducing agent, on the 
mitotic ring arrangement (Table 3) and on spin-
die morphology by anti-tubulin antibody staining. 
As controls, we used untreated cells. Out of more 
than 2000 evaluated rings, only one showed a 
displaced chromosome and spindie morphology 
looked normal after 5-azacytidine treatment. This 
was comparable to vehicle controls which did not 
have any displaced chromosomes. The DES-
Fig. 5. SupravitalUV microscopy observation of live SHE cells during the course of mitosis. Chromatin material is visible due to 
bisbenzimid staining. (A) Anaphase chromatid separation. (B) Telophase with chromatid bridge. 
treated cells showed distorted spindies along with 
an elevated number of rings with displaced chro-
mosomes (12 of 264 rings) from the metaphase 
plate. The DES-induced disturbance of the 
metaphase ring arrangement occurred during the 
4-h treatment and, therefore, was an effect on 
cells that were in G 2 or mitosis. To exclude the 
possibility that 5-azacytidine might only have an 
effect on the metaphase ring arrangement after it 
has been integrated into the DNA in S-phase, we 
investigated different time points up to 5 h after 
the 4-h treatment. However, at none of the obser-
vation times did 5-azacytidine have any de-
tectable effect on the formation of the metaphase 
plate. 
To investigate 5-azacytidine treated cells dur-
ing the course of mitosis, we used supravital UV 
microscopy to visualize the distribution of chro-
matin elements throughout mitosis. L5178Y cells 
grow in suspension and do not attach to the 
observation chamber. Therefore, SHE cells were 
used for this purpose. We observed that the de-
velopment of the metaphase plate from prophase 
to metaphasewas normal in 5-azacytidine-treated 
cells. This is consistent with the metaphase ring 
arrangement results and indicates that there were 
no immediate, visible effects due to 5-azacytidine 
treatment. However, the cells showed impaired 
chromatid disjunction at the onset of anaphase 
which resulted in chromatid bridges which some-
times were sustained into interphase (Fig. 5). In 
20 control mitoses, the one chromatid bridge that 
still existed in ana-telophase (5%) developed a 
normal interphase. We followed 16 mitoses in the 
first 4 h after 5-azacytidine addition. Of these, 
the one cell (- 6%) showing an ana-telophase 
chromatid bridge developed a normal interphase. 
At later observation times (4-30 h after 5-
azacytidine addition), 7 of 33 ( - 21%) mitoses 
followed showed ana-telophase bridges; 2 of these 
(- 6%) persisted until interphase. Thus, since all 
the mitoses that were followed during the first 4 
h after 5-azacytidine addition seemed normal, we 
hypothesized that 5-azacytidine bad to be inte-
grated into the DNA during S phase for its effect 
on mitosis to appear in late metaphase. 
We also noted that, in some cases, the chro-
mosomes in cells treated with 5-azacytidine were 
not able to separate during mitosis (endomitosis). 
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This occurred once in 20 control mitoses, once in 
16 mitoses followed at 20-30 h after 5-azacyti-
dine addition, and in 11 of 17 mitoses (65%) 
between 4 and 10 h after 5-azacytidine addition. 
This last effect occurred during the first mitosis 
after 5-azacytidine treatment. 
Discussion 
In this paper we demoostrate that 5-azacyti-
dine induces micronuclei in L5178Y cells at con-
centrations at which we and others have previ-
ously reported its mutagenic activity at the tk 
locus (Amacher and Turner, 1987; McGregor et 
al., 1989). The results of the CREST, c-banding 
and hybridization experiments suggest that the 
induced micronuclei contained mostly chromoso-
mal fragments, although the presence of some 
whole chromosomes is possible. 
Our results are consistent with other reports of 
the compound's clastogenicity (Call et al., 1986; 
Shelby, 1992; Stopper et al., 1992; Fucik, 1970; 
Walker et al., 1987). However, Van Hummelen 
and coworkers (Van Hummelen et al., 1992) as-
serted that 5-azacytidine is an aneugen. These 
investigators reported that this compound in-
duced micronuclei in mouse bone-marrow cells in 
vivo and that the micronuclei contained whole 
chromosomes. They found that approximately 
80% of the micronuclei induced by 5-azacytidine 
in mouse bone marrow are centromere-positive. 
In their paper they argue that CREST antibody 
staining results can be artifactual, especially with 
a compound like 5-azacytidine because, by chang-
ing the methylation status of the cep.tromere, the 
chemical probably inactivates kinetochore pro-
teins resulting in kinetochore-negative micronu-
clei that contain whole chromosomes. This hy-
pothesis is not supported by our data, in which 
the CREST antibody staining and the cen-
tromeric heterochromatin DNA-staining results 
are similar suggesting that only a small percent-
age of micronuclei could contain whole chromo-
somes with inactivated kinetochores. These re-
sults support the conclusion that 5-azacytidine-in-
duced micronuclei contain mostly chromosome 
fragments. 
Our data demonstrate that 5-azacytidine did 
not induce micronuclei via interference with 
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chromosome distribution during prophase or 
metaphase or by Iack of kinetochore binding, 
further ruling out the possibility that 5-azacyti-
dine has predominantly aneugenic activity. There 
was no effect on metaphase ring arrangements 
and spindie morphology. On the other band, our 
data do demoostrate that visible effects of 5-
azacytidine could be observed after the cells en-
tered anaphase. Chromatid bridges were ob-
served in anaphase that sustained until telophase 
and even in some cases until interphase. In the 
first mitosis after 5-azacytidine treatment and re-
moval, we observed an increase in the rate of 
endomitosis. At this first mitosis, the methylation 
patterns at individual CpG sequences on the two 
DNA strands would be different, some CpG se-
quences being methylated on both strands and 
others hemimethylated (methylated on one 
strand) due to 5-azacytidine incorporation. In 
subsequent mitoses, these CpG sequences of both 
strands would be methylated in 3/4 of the 
progeny cells; the remaining 114 would be hy-
pomethylated (contain unmethylated CpG se-
quences on both strands). Thus, only in the first 
mitosis could a hemimethylated state have ex-
isted. It appears that maximum endomitosis oc-
curred during mitosis of cells with hemimeth-
ylated DNA. It has been shown that, in addition 
to endoreduplication, maximal SCE induction also 
occurred during the first mitosis after treatment 
(Hori, 1983). 
Although the effects of 5-azacytidine were not 
visible in supravital UV microscopy until anaphase 
and telophase, our BrdU incorporation sturlies 
showed that the cells had to be in S phase at the 
time of exposure for micronuclei tobe formed. 
There are two intemally consistent hypotheses 
that can explain the BrdU incorporation data. In 
the first we assume that 5-azacytidine can induce 
DNA repair in the nucleus, but not in the mi-
cronucleus and that this repair response is acti-
vated through a mechanism that does not involve 
incorporation of 5-azacytidine into DNA and, 
therefore, operates outside of S phase. Whether 
5-azacytidine can induce repair by its incorpora-
tion into DNA is not relevant to this scenario 
because such an effect would show the presence 
of BrdU in both the micronuclei and nuclei and 
could not be distinguished from normal replica-
tion. In this scenario, the increase in cells treated 
with 5-azacytidine showing BrdU in both the nu-
clei and micronuclei would be due to incorpora-
tion during S phase replication. An increase of 
cells in the second category where BrdU is incor-
porated into the nucleus but not the micronu-
cleus would be due to repair. In the final category 
in which BrdU was not incorporated into the cell 
at all, 5-azacytidine treatment decreased the 
number of cells with no BrdU in either the nu-
cleus or micronucleus. Thus, the loss of micronu-
clei with no BrdU would have to be due to a shift 
of some of the cells that would have appeared in 
the third category if treated only with the vehicle 
control to the second category in which the nu-
cleus, but not the rnicronucleus, contains BrdU 
due to repair. 
Based on our understanding of how 5-azacyti-
dine interacts with cells, the assumption that 5-
azacytidine can induce repair when applied to 
cells during non-replicative phases of the cell 
cycle is difficult to accept since 5-azacytidine is 
not known to bind to DNA. There is no evidence 
that 5-azacytidine induces repair; in fact a report 
examining the effects of this compound on un-
scheduled DNA synthesis (UDS) in SHE cells 
was negative (Stopper et al., 1992). However, it is 
thought that UDS is sensitive only to !arge patch 
repair. Whether the assumptions made are valid 
or not, this scenario asserts that SHE cells must 
be in S phase for micronuclei to be induced by 
5-azacytidine. 
In the second mechanism we assume that 5-
azacytidine does not induce repair and that BrdU 
incorporation into nuclear DNA implies that the 
cells were exposed in S phase. In this scenario, 
5-azacytidine induces micronuclei when incorpo-
rated into DNA during replication as evidenced 
by the increase observed in the first category 
(BrdU incorporation into nuclear and micronu-
clear DNA). To explain the effects seen in the 
next two categories, we invoke an observation by 
Poot (Poot et al., 1990) that 5-azacytidine in-
duces, among other cell cycle disturbances, a 
shortening of G1• Any cells with pre-existing mi-
cronuclei that would have been in G1 if not 
treated with 5-azacytidine, but now are in early S 
phase because of the treatment, may have incor-
porated BrdU into the nuclear, but not the mi-
cronuclear DNA. This would explain both the 
increase in 5-azacytidine-induced micronuclei in 
the second category and the reduction of mi-
cronuclei in 5-azacytidine-treated cells compared 
to the control in the third category. In this sce-
nario, 5-azacytidine would simply induce a shift 
in micronuclei containing cells in category 3 to 
category 2. 
Whichever of these seenarios is correct, it 
should be noted that both postulate that the 
exposure of SHE cells to 5-azacytidine in S phase 
will result in micronucleus induction. This is the 
main conclusion to be drawn from this experi-
ment. 
In contrast, DES, which induced micronuclei 
containing whole chromosomes, showed no in-
crease in BrdU positive micronuclei when the 
cells were exposed in S phase (category 1). How-
ever, an increase in BrdU-negative micronuclei in 
the presence of nuclear incorporation of BrdU 
was registered. This may suggest that DES 
changes the cell cycle through mechanisms simi-
lar to that proposed for 5-azacytidine. The nuro-
ber of cells showing no BrdU signal in the nu-
cleus and the micronucleus increased after DES 
treatment. These cells could have been in G2 
phase during treatment and formed micronuclei 
during the mitoses imrnediately following treat-
ment or they could haye been in M phase, in 
which case the micronuclei would have been 
formed in the same mitosis in which treatment 
occurred. Our data for DES are in agreement 
with the published ideas about that compound's 
mechanism of micronucleus induction (Schiff-
mann and DeBoni, 1991). 
Our observation of a delay between 5-azacyti-
dine treatment and the occurrence of mitotic 
darnage and our conclusion that 5-azacytidine 
bad to be integrated into DNA in S-phase to 
manifest its effects in mitosis is consistent with 
reports that 5-azacytidine, when added to cells 
during late S phase, prevents the condensation 
of R-band positive heterochromatin (Viegas-
Pequignot and Dutrillaux, 1981). Hori also re-
ported that pulse treatment of CHO cells and 
kangaroo-rat cells during S phase resulted in seg-
mented metaphase chromosome decondensation 
(Hori, 1983). The most sensitive sites, in that 
study, appeared to be heterochromatic regions of 
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chromosomes which replicated late in S phase. 
The obsetvation that the effects of 5-azacyti-
dine are not produced until late metaphase is 
also supported by our observation that 5-azacyti-
dine bad no effect on spindie morphology and 
that the metaphase plate looked normal. These 
results contrasted with those obtained with DES 
which showed effects on spindie morphology and 
the metaphase plate. Albertini (Albertini et al., 
1988) has also reported that spindie tubulin as-
sembly is not influenced by 5-azacytidine treat-
ment. 
Thus, all our data taken tagether indicate that 
5-azacytidine is predominantly a clastogen. Al-
though it is possible that 5-azacytidine has some 
aneugenic properties, we could not establish the 
existence of any such mechanism. 
5-Azacytidine is often used to induce hy-
pomethylation in cells. The biological conse-
quences resulting from this treatment are usually 
attributed to this change in methylation which is, 
in turn, generally assumed to interfere with the 
transcriptional machinery directly. However, the 
chemical has other biochemical effects that could 
also have biological consequences and often these 
are ignored. Given what is known about the ef-
fects of 5-azacytidine on the DNA structure and 
its ability to induce chromosomal aberrations 
when incorporated into DNA during S phase, we 
have to consider that the mechanism Ieading to 
transcriptional changes are more complicated 
than simply a change in methylation. Methylated 
regions can undergo transitions from the B to the 
Z form of DNA at physiological conditions, 
whereas, if these regions were unmethylated, they 
would exist only in the B form (Banerjee and 
Benedict, 1979; Nickol et al., 1982). DNA 
stretches containing unmethylated GC regions are 
less stable than those that are methylated ( Collins 
and Myers, 1987). Methylated CpG rieb regions 
of DNA are more resistant to micrococcal nucle-
ase digestion than bulk DNA (Keshet et al., 1986; 
Razin and Cedar, 1977; Solage and Cedar, 1978). 
In an added layer of complication, Mspl, which is 
able to cut CCGG sequences in naked DNA 
whether or not the intemal C is methylated, is 
unable to cleave methylated CpGs in nuclei sug-
gesting that DNA binding proteins may have dif-
ferent affmities to methylated and unmethylated 
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sites (Antequera et al., 1989, 1990; Meehan et al., 
1989). CpG rieb heterochromatic sites are targets 
for 5-azacytidine induced demethylation and also 
for decondensation due to a more open confor-
mation. This may make those stretches more ac-
cessible to repair enzymes resulting in regions 
that are more susceptible to the production of 
chromosomal aberrations induced by these en-
zymes (Savage, 1975). Our results with ethionine, 
which is considered to be a hypomethylating 
agent, supports this idea. As observed by others, 
GC rich regions are particularly sensitive to the 
decondensation effects of 5-azacytidine (Fucik et 
al., 1970; Hori, 1983; Parrow et al., 1989; Schmid 
et al., 1984). The decondensation or out of cycle 
condensation effects may be responsible for the 
formation of the chromatid bridges (incomplete 
untangling of the chromatids) before separation 
in anaphase. These chromatid .bridges may be 
caused by the same mechanism that results in the 
endomitosis that we and others have observed 
(Fucik et al., 1970; Hori, 1983; Stopper et al., 
1992). As an example, DNA topoisemerase II, an 
enzyme with an essential role in chromatid sepa-
ration, may be impaired in its function when 
interacting with hemi- or hypo-methylated or un-
dercondensed DNA. This has been suggested for 
minor groove binding agents like berenil which 
may cause inhibition of topoisemerase II due to 
their effects on chromosome conformation (Poot 
et al., 1990) and is supported by our findings with 
berenil. We could envision a mechanism whereby 
the formation of chromatid bridges results in 
breakage of chromatids and the chromatin frag-
ments are enclosed in micronuclei. The existence 
of such a mechanism is supported by our Observa-
tion that 80% of the micronuclei did not contain 
whole chromosomes, although we did not find 
chromatin fragments lying apart from the 
metaphase ring arrangement. This can only be 
explained if chromosome breakage occurred after 
the formation of the metaphase plate. However, 
the experiments of Davidson and ooworkers 
(Davidson et al., 1992) seem to contradict this 
mechanism. Using phase contrast video mi-
croscopy, they also observed that 5-azacytidine-
treated cells were unable to separate in the first 
cell division after treatment. This was probably 
due to endomitosis. They also observed that cel-
Iular bridges were formed. Nevertheless, they 
concluded that these bridges did not break. 
Therefore, we cannot rule out other mechanisms 
of 5-azacytidine mediated micronucleus induc-
tion, such as elimination of improperly condensed 
chromatin material via micronucleus formation 
during the interphase of the cell cycle. 
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